pomalidomide has been researched along with Minimal Disease, Residual in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Branagan, AR; Dhodapkar, KM; Dhodapkar, MV; Flavell, RA; Verma, R; Xu, ML | 1 |
2 review(s) available for pomalidomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
1 other study(ies) available for pomalidomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; SOXB1 Transcription Factors; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |